The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment for severe low blood sugar levels (hypoglycaemia) in diabetics ...

Eli Lilly’s intranasal formulation of glucagon – called Baqsimi – is the first alternative to injectable glucagon for severe hypoglycaemia, which typically occurs when people with diabetes ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Under the Other revenues segment, AMPH records net revenues from the sales of Baqsimi, which AMPH acquired from Eli Lilly in June 2023. Baqsimi is a dry nasal spray to treat very low blood sugar ...